We report a case of a frail 68-year-old woman with stage 4 pancreatic carcinoma harbouring a fibroblastic growth factor receptor 2 () fusion who achieved a durable complete response after treatment with erdafitinib a pan-FGFR inhibitor. The fusion was detected on comprehensive tumour somatic mutation profiling. There is ongoing complete response at 10 months after initiation of erdafitinib. Transient central serous retinopathy, grade 2 hyperphosphataemia and diarrhoea were the adverse events encountered.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438717 | PMC |
| http://dx.doi.org/10.1136/bcr-2021-244271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Program Directors' Assessments of US Medical Graduates' Transition to Residency.
JAMA Netw Open
January 2025
Transforming Medical Education, Association of American Medical Colleges, Washington, DC.
Importance: Medical school graduates across specialties should be prepared for the start of postgraduate year 1 (PGY-1). Assessments by program directors (PDs) may offer insight to differences in preparedness across medical specialties.
Objective: To investigate whether PD assessments of their PGY-1 residents' performance during the transition to residency differed by specialty category.
Virtual Neonatal Resuscitation Curriculum for Emergency Medical Services (EMS) to Improve Out-of-Hospital Newborn Care.
Prehosp Emerg Care
January 2025
Department of Emergency Medicine, Oregon Health & Science University, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd Portland, OR 97239.
Objectives: Out-of-hospital births are associated with a 2-to 11-fold increased risk of death compared to in-hospital births and are growing. Emergency Medical Services (EMS) clinicians have limited exposure to hospital birth emergencies, and there is no standardized prehospital neonatal resuscitation curriculum. Neonatal Resuscitation Program (NRP) guidelines are the standard of care for infants born in the United States but focuses on in-hospital births and is not easily applied to EMS.
View Article and Find Full Text PDFMicrowave therapy for the treatment of resistant plantar warts: a randomized, placebo-controlled clinical trial.
Arch Dermatol Res
January 2025
Hautpartner Lübeck, Lindenplatz 6, 23554, Lübeck, Germany.
Plantar warts, or verrucae plantares, are skin lesions on the soles of the feet caused by human papillomavirus (HPV). These warts are prevalent and affect up to 33% of children and 3.5% of adults.
View Article and Find Full Text PDFRAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
Clin Cancer Res
December 2024
Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Purpose: The randomized GeparOla trial reported comparable pathological complete response (pCR) rates with neoadjuvant containing olaparib vs. carboplatin treatment. Here, we evaluate the association between functional homologous repair deficiency (HRD) by RAD51 foci and pCR, and the potential of improving patient selection by combining RAD51 and stromal tumor infiltrating lymphocytes (sTILs).
View Article and Find Full Text PDFOdronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: Primary analysis of the ELM-1 study.
Blood
December 2024
Dana-Farber Cancer Institute, Boston, Massachusetts, United States.
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) progressing after chimeric antigen receptor T-cell therapy (CAR T) have dismal outcomes. The prespecified post-CAR T expansion cohort of the ELM-1 study investigated the efficacy and safety of odronextamab, a CD20×CD3 bispecific antibody, in patients with disease progression after CAR T. Sixty patients received IV odronextamab weekly for 4 cycles followed by maintenance until progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!